Natick, Mass. – December 1, 2025 – Pillar Biosciences, the leader in Decision Medicine™, today
announced that the Centers for Medicare & Medicaid Services (CMS) has finalized its pricing
determination for oncoReveal CDx. Following its preliminary decision in August 2025, CMS
confirmed a crosswalk-based payment rate of $1,352.09, effective for claims with dates of service on
or after January 1, 2026.
“We are pleased with CMS’s pricing decision,” said Gang Song, Ph.D., Founder, Executive
Chairman and Chief Executive Officer of Pillar Biosciences. “This determination will help Medicare
beneficiaries gain access to high-quality cancer diagnostics.”
“This is another exciting milestone in the launch of oncoReveal CDx,” said Brian Wright, Chief
Marketing Officer of Pillar Biosciences. “As the first PMA-approved multi-cancer IVD kit available in
the U.S. market, oncoReveal CDx offers highly accurate and actionable NGS-based results. With
more than 66 million Americans covered by Medicare, this payment rate will help ensure broad
patient access to precision oncology testing.”
About Pillar Biosciences
Pillar Biosciences is the leader in Decision Medicine™, leveraging next-generation sequencing
(NGS) technology to deliver highly accurate, sensitive, and cost-effective testing solutions that
improve treatment selection for cancer patients—from tumor profiling to therapy selection and
recurrence monitoring. Powered by its proprietary SLIMamp® and PiVAT® technologies, Pillar’s
localized testing model reduces diagnostic costs and increases access to complex NGS testing
worldwide. The company currently offers more than 20 NGS testing kits in IVD and RUO formats,
with additional panels in development. Pillar Biosciences is headquartered in Natick, Massachusetts.
For more information, visit www.pillarbiosci.com or follow Pillar Biosciences on LinkedIn.
More Information:
Brian Wright
Chief Marketing Officer
Pillar Biosciences
602-540-9522
wrightb@pillarbiosci.com
